Loading…
Underlying
Underlying Price
$8.28
Type
Call
Strike
10
Expiration
Nov 20, 2026
DTE
31d
Moneyness
OTM
Intrinsic
$0.00
IBRX 10 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.18 | -55.00% | 1,199 | 2,764 |
| Oct 30, 2026 | 10d | $0.32 | -54.29% | 35 | 953 |
| Nov 6, 2026 | 17d | $0.70 | -30.00% | 65 | 195 |
| Nov 13, 2026 | 24d | $0.70 | -40.68% | 9 | 38 |
| Nov 20, 2026 | 31d | $0.80 | -38.46% | 311 | 6,043 |
| Nov 27, 2026 | 38d | $1.00 | -31.03% | 3 | 82 |
| Dec 18, 2026 | 59d | $1.30 | +0.00% | 8 | 8 |
| Jan 15, 2027 | 87d | $1.55 | -26.19% | 2,280 | 72,472 |
| Mar 19, 2027 | 150d | $2.20 | -21.43% | 192 | 1,352 |
| Apr 16, 2027 | 178d | $2.10 | -27.84% | 8 | 135 |
| May 21, 2027 | 213d | $2.50 | -34.21% | 11 | 83 |
| Aug 20, 2027 | 304d | $3.48 | +2.35% | 8 | 364 |
| Nov 19, 2027 | 395d | $3.78 | -0.53% | 20 | 85 |
| Jan 21, 2028 | 458d | $3.20 | -14.44% | 677 | 11,278 |
| Mar 17, 2028 | 514d | $4.00 | +0.00% | 3 | 360 |
| Jan 19, 2029 | 822d | $4.50 | -4.46% | 6 | 2,644 |
IBRX Nearby Strikes · Nov 20, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 4 C | $5.45 | -12.10% | 16 | 48 | ITM |
| 5 C | $4.85 | -6.73% | 4 | 3 | ITM |
| 6 C | $3.50 | -12.50% | 53 | 147 | ITM |
| 7 C | $2.40 | -29.82% | 38 | 1,112 | ITM |
| 8 C | $1.75 | -28.57% | 129 | 1,390 | ITM |
| 9 C | $1.10 | -38.89% | 40 | 6,064 | OTM |
| 10 C | $0.80 | -38.46% | 311 | 6,043 | OTM |
| 11 C | $0.55 | -37.50% | 630 | 5,915 | OTM |
| 12 C | $0.36 | -40.00% | 197 | 7,831 | OTM |
| 13 C | $0.25 | -39.02% | 2 | 1,184 | OTM |
| 14 C | $0.30 | -11.76% | 40 | 2,285 | OTM |
| 15 C | $0.15 | -40.00% | 45 | 1,348 | OTM |
| 16 C | $0.28 | -20.00% | 7 | 1,441 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.